Journal
LEUKEMIA & LYMPHOMA
Volume 62, Issue 3, Pages 669-678Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1838509
Keywords
Quality of life; tyrosine kinase inhibitors; symptoms; chronic myeloid leukemia; patient-reported outcomes
Categories
Funding
- EORTC Quality of Life Group [004/2015]
Ask authors/readers for more resources
The study validated the EORTC QLQ-CML 24 questionnaire with 782 CML patients internationally, indicating its value in assessing HRQOL in CML patients. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.66 to 0.83, and reference values stratified by age and sex were generated for future studies.
Health-related quality of life (HRQOL) assessment is important to facilitate decisions in the current treatment landscape of chronic myeloid leukemia (CML). Therefore, the availability of a validated HRQOL questionnaire, specifically developed for CML patients treated with tyrosine kinase inhibitors (TKIs), may enhance quality of research in this area. We performed an international study including 782 CML patients to assess the validity of the EORTC QLQ-CML 24 questionnaire, and to generate HRQOL reference values to facilitate interpretation of results in future studies. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.66 to 0.83. In the confirmatory factor analysis, all standardized factor loadings exceeded the threshold of 0.40 (range 0.49-0.97), confirming the hypothesized scale structure. Reference values stratified by age and sex were also generated. Our findings support the use of the EORTC QLQ-CML 24, in conjunction with the EORTC QLQ-C30, as a valuable measure to assess HRQOL in CML patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available